PMID- 25335734
OWN - NLM
STAT- MEDLINE
DCOM- 20150703
LR  - 20221207
IS  - 1875-8592 (Electronic)
IS  - 1574-0153 (Linking)
VI  - 14
IP  - 6
DP  - 2014
TI  - Metronomic gemcitabine targeted tumor vascular microenvironment decreases the 
      population of CD133(+) cells in hepatocarcinoma xenografts.
PG  - 427-33
LID - 10.3233/CBM-140419 [doi]
AB  - Recently, compelling evidence shows that cancer stem-like cells (CSLC) are 
      thought to be critical for initiation and propagation of many types of cancers. 
      Most of CSLC are dependent upon the vascular microenvironments that promote their 
      long-term growth and self-renewal. However, it is not known if when we disrupted 
      their vascular microenvironments, CSLC would be eliminated. Considering these 
      possibilities, we have investigated the influence of different chemotherapy 
      regimens on the CSLC population of hepatocarcinoma xenografts model. The mouse 
      models of hepatocarcinoma were treated with different therapeutic regimens: 
      low-dose metronomic (LDM) regimens, combination therapies of Bolus dose and 
      low-dose metronomic regimens, for the purpose of comparison, a conventional 
      cytotoxic schedule of maximum tolerated dose (MTD) chemotherapy using gemcitabine 
      (GEM). All therapies produced a significant tumor growth delay. LDM GEM and 
      Bolus+LDM GEM significantly reduced the tumor spheres, whereas MTD GEM had no 
      effect on the tumor spheres. Furthermore, Bolus+LDM GEM could more significantly 
      decrease both the population of CSLC and the levels of viable endothelial 
      progenitor cells (EPC). Overall, our data indicate that Bolus+LDM GEM is a potent 
      treatment regimen for inhibiting angiogenesis, attacking the tumor vascular 
      microenvironments, and decreasing the population of CSLC. Targeting the unique 
      microenvironment of CSLC may be the key to effective cancer therapy, and shows 
      great promise for the clinical practice.
FAU - Yi, Shan-Yong
AU  - Yi SY
AD  - Department of Oncology, Zhengzhou Central Hospital Affiliated to Zhengzhou 
      University, Zhengzhou, Henan, China.
FAU - Ruan, Jing
AU  - Ruan J
AD  - Department of Optometry, College of Optometry of Tianjin Medical University, 
      Tianjin, China.
FAU - Zhao, Ling
AU  - Zhao L
AD  - Department of Oncology, Zhengzhou Central Hospital Affiliated to Zhengzhou 
      University, Zhengzhou, Henan, China.
FAU - Ke, Yang
AU  - Ke Y
AD  - Department of Oncology, Zhengzhou Central Hospital Affiliated to Zhengzhou 
      University, Zhengzhou, Henan, China.
FAU - Li, Xiang-Nan
AU  - Li XN
AD  - Department of Chest Surgery, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, Henan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Cancer Biomark
JT  - Cancer biomarkers : section A of Disease markers
JID - 101256509
RN  - 0 (AC133 Antigen)
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antigens, CD)
RN  - 0 (Glycoproteins)
RN  - 0 (PROM1 protein, human)
RN  - 0 (Peptides)
RN  - 0 (Prom1 protein, mouse)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - AC133 Antigen
MH  - Angiogenesis Inhibitors/administration & dosage
MH  - Animals
MH  - Antigens, CD/genetics
MH  - Carcinoma, Hepatocellular/*drug therapy/genetics/pathology
MH  - Deoxycytidine/administration & dosage/*analogs & derivatives
MH  - Endothelial Cells/drug effects/metabolism/pathology
MH  - Glycoproteins/genetics
MH  - Humans
MH  - Liver Neoplasms/*drug therapy/genetics/pathology
MH  - Mice
MH  - Neoplastic Stem Cells/drug effects/metabolism/pathology
MH  - Neovascularization, Pathologic/*drug therapy/pathology
MH  - Peptides/genetics
MH  - Tumor Microenvironment/drug effects
MH  - Xenograft Model Antitumor Assays
MH  - Gemcitabine
OTO - NOTNLM
OT  - Metronomic chemotherapy
OT  - cancer stem-like cells
OT  - gemcitabine
OT  - hepatocarcinoma
OT  - tumor vascular microenvironment
EDAT- 2014/10/23 06:00
MHDA- 2015/07/04 06:00
CRDT- 2014/10/23 06:00
PHST- 2014/10/23 06:00 [entrez]
PHST- 2014/10/23 06:00 [pubmed]
PHST- 2015/07/04 06:00 [medline]
AID - X55P581Q075386K2 [pii]
AID - 10.3233/CBM-140419 [doi]
PST - ppublish
SO  - Cancer Biomark. 2014;14(6):427-33. doi: 10.3233/CBM-140419.